drugset / Trial / NCT03631576
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
NaSingle-groupOpen-labelTreatment
Summary
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.
Timeline
- Start
- 2018-08-10
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD123/CLL1 CAR-T Cells | Cell therapy | — | — |